StockMacro
Company, fund or insider

Help

Menu

Citius Oncology

$0.50 -41% in 6 monthsMarket cap $53.2M

CTOR on XNAS, Health Care, Citius Oncology, Inc., job postings

Measures activity, not value. Not investment advice.

Stock down 55% in a year while the company lost $46.1M over 12 months with cash of $16.6M.

  • GoodInstitutional filers up 10%, to 22 from 20 the prior quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Jun 2026

Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.

Industry
Pharmaceutical preparations (Health Care)
Website
citiusonc.com
Listed
Nasdaq, US
Last results
26 Oct 2026
Next results
expected around 22 Dec 2026 (an estimate: a year ago it reported on 23 Dec 2025)
Revenue and net income per quarter. Quarter to 30 Jun 2026: revenue $1.5M, net loss $8.9M.
Quarter to 31 Dec 2021: revenue –, net income $0Quarter to 31 Mar 2023: revenue –, net income $612KQuarter to 30 Jun 2023: revenue –, net income $616KQuarter to 30 Sep 2023: revenue –, net income $158KQuarter to 31 Dec 2023: revenue –, net income -$4.7MQuarter to 31 Mar 2024: revenue –, net income $490KQuarter to 30 Jun 2024: revenue –, net income $252KQuarter to 30 Sep 2024: revenue –, net income -$6.8MQuarter to 31 Dec 2024: revenue –, net income -$6.7MQuarter to 31 Mar 2025: revenue –, net income -$7.7MQuarter to 30 Jun 2025: revenue –, net income -$5.4MQuarter to 30 Sep 2025: revenue –, net income -$5.0MQuarter to 31 Dec 2025: revenue $3.9M, net income -$5.5MQuarter to 31 Dec 2025: revenue $3.9M, net income -$5.5MQuarter to 31 Mar 2026: revenue $1.7M, net income -$26.6MQuarter to 31 Mar 2026: revenue $1.7M, net income -$26.6MQuarter to 30 Jun 2026: revenue $1.5M, net income -$8.9MQuarter to 30 Jun 2026: revenue $1.5M, net income -$8.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $26.6M30 Jun 2026
See the numbers
Quarter toRevenueNet income
30 Jun 2026$1.5M-$8.9M
31 Mar 2026$1.7M-$26.6M
31 Dec 2025$3.9M-$5.5M
30 Sep 2025–-$5.0M
30 Jun 2025–-$5.4M
31 Mar 2025–-$7.7M
31 Dec 2024–-$6.7M
30 Sep 2024–-$6.8M
30 Jun 2024–$252K
31 Mar 2024–$490K
31 Dec 2023–-$4.7M
30 Sep 2023–$158K
30 Jun 2023–$616K
31 Mar 2023–$612K
31 Dec 2021–$0
Fundamentals, 12 months to 30 Jun 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$46.1M -$26.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.47 -$0.38
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -127% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $16.6M $112
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $6.4M –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$10.2M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.16 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.43
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.2 2.0

Latest = 12 months to 30 Jun 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Citius OncologyCTOR (this company) $53.2Mloss–––
Impact BioMedicalIBO $53.3M–over 999––
Xilio TherapeuticsXLO $53.4Mloss0.97+73%-20.9%
XBiotechXBIT $52.7Mloss–––
LifevantageLFVN $52.6M19.30.31-25%1.6%
Boundless BioBOLD $54.8Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+10%

22 13F filers vs 20

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

15%

13.7M shares held by 13F filers (30 Sep 2026) of 93.0M outstanding (13 Aug 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.2%

202K shares sold short (30 Oct 2026) of 93.0M outstanding (13 Aug 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.2

202K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-11%

227K shares sold short in the report before, 202K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

22%

22% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 40%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

4 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $0.50 on 20 Nov 2026, -55% over 12 months (12-month range $0.49 to $1.64)

  • Sharp change
  • 8-K and other filings
Revenue per quarter. Revenue $1.5M in the latest quarter.
Institutional holders (13F filers). 22 13F filers reported holding it in the latest 13F quarter, +57% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
12 Aug 20268-K and other filingsDirector or officer change
12 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Apr 20268-K and other filingsDelisting notice or listing transfer
14 Apr 2026Sharp changeShort interest spike: short interest spike, 1.1M vs usual 239K (2026-03-31); 5.9x the same period a year earlier
31 Mar 2026Sharp changeShort interest spike: short interest spike, 1.0M vs usual 229K (2026-03-13); 37.4x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 985K vs usual 214K (2026-02-27); 26.1x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 914K vs usual 193K (2026-02-13); 28.0x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 1.2M vs usual 175K (2026-01-30); 32.7x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 1.2M vs usual 160K (2026-01-15); 52.6x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 984K vs usual 143K (2025-12-31); 11.7x the same period a year earlier
30 Dec 2025Sharp changeShort interest spike: short interest spike, 651K vs usual 125K (2025-12-15); 8.4x the same period a year earlier
27 Oct 20258-K and other filingsDirector or officer change
19 Sep 20258-K and other filingsDirector or officer change
19 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Jul 20258-K and other filingsRegistered new securities for sale (S-1)
14 Jul 20258-K and other filingsRegistered new securities for sale (S-1)
25 Apr 20258-K and other filingsDelisting notice or listing transfer
16 Aug 20248-K and other filingsDirector or officer change
16 Aug 20248-K and other filingsChanged its auditor
16 Aug 20248-K and other filingsCompleted an acquisition or asset sale
3 Aug 20248-K and other filingsDirector or officer change
3 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 May 20248-K and other filingsReport will be filed late
2 Apr 20248-K and other filingsReport will be filed late
14 Nov 20238-K and other filingsReport will be filed late
14 Aug 20238-K and other filingsReport will be filed late
31 Mar 20238-K and other filingsReport will be filed late
12 Sep 20228-K and other filingsRegistered new securities for sale (S-1)
29 Jul 20228-K and other filingsRegistered new securities for sale (S-1)
24 May 20228-K and other filingsRegistered new securities for sale (S-1)
11 May 20228-K and other filingsRegistered new securities for sale (S-1)
1 Apr 20228-K and other filingsRegistered new securities for sale (S-1)
8 Mar 20228-K and other filingsRegistered new securities for sale (S-1)
Revenue per quarter
Quarter ended 31 Dec 2025: $3.9M; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $1.7M; public on 16 May 2026
Quarter ended 30 Jun 2026: $1.5M; public on 15 Aug 2026
Institutional holders (13F filers)
30 Sep 2024 report: 5; public on 14 Nov 2024
31 Dec 2024 report: 11; public on 14 Feb 2025
31 Mar 2025 report: 6; public on 15 May 2025
30 Jun 2025 report: 7; public on 14 Aug 2025
30 Sep 2025 report: 14; public on 14 Nov 2025
31 Dec 2025 report: 18; public on 17 Feb 2026
31 Mar 2026 report: 12; public on 15 May 2026
30 Jun 2026 report: 20; public on 14 Aug 2026
30 Sep 2026 report: 22; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is total debt at period end: short- and long-term borrowings at $6.4M (30 Jun 2026), higher than 100% of its own history.
  • Revenue per quarter: Revenue $1.5M in the latest quarter.
  • Institutional holders (13F filers): 22 13F filers reported holding it in the latest 13F quarter, +57% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

22 institutions reported shares at the end of Q3 2026, 15% of the shares outstanding; 7 opened a position, 4 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Armistice Capital, LLC8.3M8.97%$8.4M-366K-4.2%
Bank of America Corp3.8M4.12%$3.9M+150%
Vanguard Capital Management LLC546K0.59%$552KNo change
Geode Capital Management, LLC282K0.30%$285K+37K+15%
Vanguard Fiduciary Trust Co175K0.19%$177K+53K+44%
Citadel Advisors LLC126K0.14%$127K+35K+39%
IFP Advisors, Inc107K0.12%$108KNo change
PFS Signature Wealth LLC107K0.12%$108K
Northern Trust Corp46K0.05%$46KNo change
State Street Corp43K0.05%$43KNo change

Company events

All 41 company events

In 12 months: 2 major agreements, 1 delisting notice, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
12 Aug 2026Director or officer change8-K
6 May 2026Signed a major agreementSame filing: took on new debt, sold shares privately8-K
28 Apr 2026Delisting notice or listing transfer8-K
10 Dec 2025Signed a major agreementSame filing: sold shares privately8-K
27 Oct 2025Director or officer changeSame filing: shareholder vote results8-K
19 Sep 2025Director or officer changeSame filing: sold shares privately8-K
10 Sep 2025Signed a major agreementSame filing: sold shares privately8-K
18 Jul 2025Signed a major agreement8-K

The 5 newest of 48 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 12 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 12 Aug 2026Filings record

    Director or officer change

  3. 28 Apr 2026Filings record

    Delisting notice or listing transfer

  4. 11 Apr 2026Short interest and volume change

    had 1.1M shares sold short in the 31 Mar 2026 report, 5.9× the same report last year.

    Same report last year: 181K; its normal report is 239K.

    See the evidence
    This period
    1.1M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    239K
    Typical spread (median absolute deviation)
    126K
    How far from its usual level
    +4.4
    Same report last year
    181K
    History used
    593 days
    2025-03-31: 181K2025-04-15: 206K2025-04-30: 71K2025-05-15: 47K2025-05-30: 26K2025-06-13: 114K2025-06-30: 366K2025-07-15: 77K2025-07-31: 299K2025-08-15: 237K2025-08-29: 303K2025-09-15: 136K2025-09-30: 169K2025-10-15: 151K2025-10-31: 251K2025-11-14: 240K2025-11-28: 222K2025-12-15: 651K2025-12-31: 984K2026-01-15: 1.2M2026-01-30: 1.2M2026-02-13: 914K2026-02-27: 985K2026-03-13: 1.0M2026-03-31: 1.1M
    the 31 Mar 2026 report24 earlier reportsnormal: 239K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 25 Mar 2026Short interest and volume change

    had 1.0M shares sold short in the 13 Mar 2026 report, 37× the same report last year.

    Same report last year: 28K; its normal report is 229K.

    See the evidence
    This period
    1.0M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    229K
    Typical spread (median absolute deviation)
    126K
    How far from its usual level
    +4.3
    Same report last year
    28K
    History used
    575 days
    2025-03-14: 28K2025-03-31: 181K2025-04-15: 206K2025-04-30: 71K2025-05-15: 47K2025-05-30: 26K2025-06-13: 114K2025-06-30: 366K2025-07-15: 77K2025-07-31: 299K2025-08-15: 237K2025-08-29: 303K2025-09-15: 136K2025-09-30: 169K2025-10-15: 151K2025-10-31: 251K2025-11-14: 240K2025-11-28: 222K2025-12-15: 651K2025-12-31: 984K2026-01-15: 1.2M2026-01-30: 1.2M2026-02-13: 914K2026-02-27: 985K2026-03-13: 1.0M
    the 13 Mar 2026 report24 earlier reportsnormal: 229K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 11 Mar 2026Short interest and volume change

    had 985K shares sold short in the 27 Feb 2026 report, 26× the same report last year.

    Same report last year: 38K; its normal report is 214K.

    See the evidence
    This period
    985K (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    214K
    Typical spread (median absolute deviation)
    119K
    How far from its usual level
    +4.4
    Same report last year
    38K
    History used
    561 days
    2025-02-28: 38K2025-03-14: 28K2025-03-31: 181K2025-04-15: 206K2025-04-30: 71K2025-05-15: 47K2025-05-30: 26K2025-06-13: 114K2025-06-30: 366K2025-07-15: 77K2025-07-31: 299K2025-08-15: 237K2025-08-29: 303K2025-09-15: 136K2025-09-30: 169K2025-10-15: 151K2025-10-31: 251K2025-11-14: 240K2025-11-28: 222K2025-12-15: 651K2025-12-31: 984K2026-01-15: 1.2M2026-01-30: 1.2M2026-02-13: 914K2026-02-27: 985K
    the 27 Feb 2026 report24 earlier reportsnormal: 214K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 26 Feb 2026Short interest and volume change

    had 914K shares sold short in the 13 Feb 2026 report, 28× the same report last year.

    Same report last year: 33K; its normal report is 193K.

    See the evidence
    This period
    914K (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    193K
    Typical spread (median absolute deviation)
    113K
    How far from its usual level
    +4.3
    Same report last year
    33K
    History used
    547 days
    2025-02-14: 33K2025-02-28: 38K2025-03-14: 28K2025-03-31: 181K2025-04-15: 206K2025-04-30: 71K2025-05-15: 47K2025-05-30: 26K2025-06-13: 114K2025-06-30: 366K2025-07-15: 77K2025-07-31: 299K2025-08-15: 237K2025-08-29: 303K2025-09-15: 136K2025-09-30: 169K2025-10-15: 151K2025-10-31: 251K2025-11-14: 240K2025-11-28: 222K2025-12-15: 651K2025-12-31: 984K2026-01-15: 1.2M2026-01-30: 1.2M2026-02-13: 914K
    the 13 Feb 2026 report24 earlier reportsnormal: 193K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 11 Feb 2026Short interest and volume change

    had 1.2M shares sold short in the 30 Jan 2026 report, 33× the same report last year.

    Same report last year: 37K; its normal report is 175K.

    See the evidence
    This period
    1.2M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    175K
    Typical spread (median absolute deviation)
    114K
    How far from its usual level
    +6.1
    Same report last year
    37K
    History used
    533 days
    2025-01-31: 37K2025-02-14: 33K2025-02-28: 38K2025-03-14: 28K2025-03-31: 181K2025-04-15: 206K2025-04-30: 71K2025-05-15: 47K2025-05-30: 26K2025-06-13: 114K2025-06-30: 366K2025-07-15: 77K2025-07-31: 299K2025-08-15: 237K2025-08-29: 303K2025-09-15: 136K2025-09-30: 169K2025-10-15: 151K2025-10-31: 251K2025-11-14: 240K2025-11-28: 222K2025-12-15: 651K2025-12-31: 984K2026-01-15: 1.2M2026-01-30: 1.2M
    the 30 Jan 2026 report24 earlier reportsnormal: 175K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 28 Jan 2026Short interest and volume change

    had 1.2M shares sold short in the 15 Jan 2026 report, 53× the same report last year.

    Same report last year: 23K; its normal report is 160K.

    See the evidence
    This period
    1.2M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    160K
    Typical spread (median absolute deviation)
    102K
    How far from its usual level
    +6.9
    Same report last year
    23K
    History used
    518 days
    2025-01-15: 23K2025-01-31: 37K2025-02-14: 33K2025-02-28: 38K2025-03-14: 28K2025-03-31: 181K2025-04-15: 206K2025-04-30: 71K2025-05-15: 47K2025-05-30: 26K2025-06-13: 114K2025-06-30: 366K2025-07-15: 77K2025-07-31: 299K2025-08-15: 237K2025-08-29: 303K2025-09-15: 136K2025-09-30: 169K2025-10-15: 151K2025-10-31: 251K2025-11-14: 240K2025-11-28: 222K2025-12-15: 651K2025-12-31: 984K2026-01-15: 1.2M
    the 15 Jan 2026 report24 earlier reportsnormal: 160K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 13 Jan 2026Short interest and volume change

    had 984K shares sold short in the 31 Dec 2025 report, 12× the same report last year.

    Same report last year: 84K; its normal report is 143K.

    See the evidence
    This period
    984K (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    143K
    Typical spread (median absolute deviation)
    97K
    How far from its usual level
    +5.9
    Same report last year
    84K
    History used
    503 days
    2024-12-31: 84K2025-01-15: 23K2025-01-31: 37K2025-02-14: 33K2025-02-28: 38K2025-03-14: 28K2025-03-31: 181K2025-04-15: 206K2025-04-30: 71K2025-05-15: 47K2025-05-30: 26K2025-06-13: 114K2025-06-30: 366K2025-07-15: 77K2025-07-31: 299K2025-08-15: 237K2025-08-29: 303K2025-09-15: 136K2025-09-30: 169K2025-10-15: 151K2025-10-31: 251K2025-11-14: 240K2025-11-28: 222K2025-12-15: 651K2025-12-31: 984K
    the 31 Dec 2025 report24 earlier reportsnormal: 143K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 25 Dec 2025Short interest and volume change

    had 651K shares sold short in the 15 Dec 2025 report, 8.4× the same report last year.

    Same report last year: 77K; its normal report is 125K.

    See the evidence
    This period
    651K (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    125K
    Typical spread (median absolute deviation)
    87K
    How far from its usual level
    +4.1
    Same report last year
    77K
    History used
    487 days
    2024-12-13: 77K2024-12-31: 84K2025-01-15: 23K2025-01-31: 37K2025-02-14: 33K2025-02-28: 38K2025-03-14: 28K2025-03-31: 181K2025-04-15: 206K2025-04-30: 71K2025-05-15: 47K2025-05-30: 26K2025-06-13: 114K2025-06-30: 366K2025-07-15: 77K2025-07-31: 299K2025-08-15: 237K2025-08-29: 303K2025-09-15: 136K2025-09-30: 169K2025-10-15: 151K2025-10-31: 251K2025-11-14: 240K2025-11-28: 222K2025-12-15: 651K
    the 15 Dec 2025 report24 earlier reportsnormal: 125K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 27 Oct 2025Filings record

    Director or officer change

  13. 19 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 19 Sep 2025Filings record

    Director or officer change

  15. 14 Jul 2025Filings record

    Registered new securities for sale (S-1)

  16. 14 Jul 2025Filings record

    Registered new securities for sale (S-1)

  17. 25 Apr 2025Filings record

    Delisting notice or listing transfer

  18. 16 Aug 2024Filings record

    Director or officer change

  19. 16 Aug 2024Filings record

    Changed its auditor

  20. 16 Aug 2024Filings record

    Completed an acquisition or asset sale

  21. 3 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 3 Aug 2024Filings record

    Director or officer change (dated 2 Aug 2024)

  23. 15 May 2024Filings record

    Report will be filed late

  24. 2 Apr 2024Filings record

    Report will be filed late

  25. 14 Nov 2023Filings record

    Report will be filed late

  26. 14 Aug 2023Filings record

    Report will be filed late

  27. 31 Mar 2023Filings record

    Report will be filed late

  28. 12 Sep 2022Filings record

    Registered new securities for sale (S-1)

  29. 29 Jul 2022Filings record

    Registered new securities for sale (S-1)

  30. 24 May 2022Filings record

    Registered new securities for sale (S-1) (dated 23 May 2022)

  31. 11 May 2022Filings record

    Registered new securities for sale (S-1)

  32. 1 Apr 2022Filings record

    Registered new securities for sale (S-1)

  33. 8 Mar 2022Filings record

    Registered new securities for sale (S-1)

  34. 20 Aug 2021Filings record

    Registered new securities for sale (S-1)

  35. 29 Jun 2021Filings record

    Registered new securities for sale (S-1)

  36. 18 May 2021Filings record

    Registered new securities for sale (S-1)

Not listed: 71 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001851484
Ticker
CTOR
Domain
citiusonc.com
Hq location
NJ|CRANFORD|07016 (1 unverified)
Name
Citius Oncology, Inc., TenX Keane Acquisition
  • SEC Form 13F institutional holdings81 data points30 Sep 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)96 records18 May 2021 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)189 data points31 Mar 2021 to 13 Aug 2026
  • FINRA short interest (twice monthly)162 data points15 Aug 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1144 data points13 Aug 2024 to 20 Nov 2026